Regulation & law · 10/09/2015
NIH to Grant Exclusive License for Cardio-Metabolic Peptide Invention to Corvidia Corporation
The National Institutes of Health is considering granting a start-up exclusive option license to Corvidia Corporation for the therapeutic use of peptides promoting lipid efflux, which could treat hypertriglyceridemia, hypercholesterolemia, and diabetes.